Efficacy and safety of docetaxel plus apatinib as a second-line treatment for advanced non-squamous non-small cell lung cancer
10.3969/j.issn.1000-8179.2017.11.245
- VernacularTitle:多西他赛联合阿帕替尼二线治疗非鳞癌非小细胞肺癌的有效性及安全性分析
- Author:
Yunjie GUO
;
Xiaohui JING
- Keywords:
docetaxel;
apatinib;
non-small cell lung cancer;
angiogenesis
- From:
Chinese Journal of Clinical Oncology
2017;44(11):544-546
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To observe the efficacy and safety of docetaxel plus apatinib as a second-line treatment for advanced non-squa-mous non-small cell lung cancer. Methods:From February 2015 to August 2016, 39 eligible patients were randomly assigned to experi-mental arm (19 cases) and control arm (20 cases). Patients in the experimental arm received 60 mg/m2 d1 docetaxel and 500 mg d1-21 apatinib for a 21-day cycle until disease progression or unacceptable toxicity occurred. Patients in the control arm received chemother-apy only. Disease control rate (DCR), incidence of adverse event, and progression-free survival (PFS) were analyzed. Results:The dis-ease control rates (DCR) in the experimental and control arms were 63.2% and 30.0%, respectively, with statistical difference (P=0.039). The experimental arm experienced many grades 3-4 hematologic adverse events with statistical difference (P=0.032). The medi-an PFS values were 5.6 months (95% CI=4.8-6.3) and 3.0 months (95% CI=1.8-4.1) with statistical difference (P=0.04). Conclusion:Docetaxel plus apatinib can be delivered safely with careful monitoring for the treatment of advanced non-squamous non-small cell lung cancer, and this treatment can significantly improve the DCR and PFS.
